Could a radiofrequency device help fight advanced breast cancer?

NCT ID NCT07672431

Not yet recruiting Disease control Sponsor: Barbara Ann Karmanos Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This pilot study tests whether adding a device called TheraBionic P1 to standard treatment can help women with metastatic triple negative breast cancer who have already tried two prior treatments. The device delivers low-level radiofrequency electromagnetic fields and is used alongside standard third-line therapy. The study aims to see if this combination improves progression-free survival and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TheraBionic P1 device (amplitude-modulated radiofrequency electromagnetic fields)
What this could lead to: If effective, this device could offer a new way to extend survival and improve quality of life for patients with advanced triple negative breast cancer.
What could go wrong: This is a small pilot study with only 24 participants, so results may not apply broadly. The device is added to standard care, and its benefit over standard care alone is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.